Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Theramex
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Theramex
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030.
Product Name : Sayana Press
Product Type : Hormone
Upfront Cash : Undisclosed
March 08, 2023
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2020
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2018
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Korean Gynecologic Oncology Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 26, 2018
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Korean Gynecologic Oncology Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Biolab Sanus Farmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 22, 2018
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Biolab Sanus Farmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2016
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : University of Washington | Wits Reproductive Health and HIV Institute | World Health Organization | Madibeng Centre for Research | Maternal Adolescent and Child Health Research | Qhakaza Mbokodo Research Clinic | The Aurum Institute NPC | Effective Care R
Deal Size : Inapplicable
Deal Type : Inapplicable
The Evidence for Contraceptive Options and HIV Outcomes Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 15, 2015
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : University of Washington | Wits Reproductive Health and HIV Institute | World Health Organization | Madibeng Centre for Research | Maternal Adolescent and Child Health Research | Qhakaza Mbokodo Research Clinic | The Aurum Institute NPC | Effective Care R
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Pfizer Inc | Tara Health Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 28, 2015
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Pfizer Inc | Tara Health Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Oregon Health and Science University | Asociación Dominicana Pro Bienestar de la Familia, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 28, 2015
Lead Product(s) : Medroxyprogesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Oregon Health and Science University | Asociación Dominicana Pro Bienestar de la Familia, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable